| Author | Vannier-Santos, Marcos André | |
| Author | Suarez-Fontes, Ana Márcia | |
| Author | Almeida-Silva, Juliana | |
| Author | Viçosa, Alessandra Lifsitch | |
| Author | Perez, Sandra Aurora Chavez | |
| Author | Hasslocher-Moreno, Alejandro Marcel | |
| Author | Estolano da Silveira, Gabriel Parreiras | |
| Author | Portela, Luciana Fernandes | |
| Author | Saraiva, Roberto Magalhaes | |
| Access date | 2023-05-16T02:01:09Z | |
| Available date | 2023-05-16T02:01:09Z | |
| Document date | 2022 | |
| Citation | VANNIER-SANTOS, Marcos André et al. Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning. In: CHAGAS DISEASE: from Cellular and Molecular Aspects of Trypanosoma cruzi-Host Interactions to the Clinical Intervention. IntechOpen, 2022. p. 1-36. | en_US |
| ISBN | 9781803556918 | |
| URI | https://www.arca.fiocruz.br/handle/icict/58419 | |
| Language | eng | en_US |
| Rights | open access | en_US |
| Title | Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning | en_US |
| Type | Book chapter | |
| Abstract | Chagas disease, caused by the protozoan Trypanosoma cruzi, is a major neglected disease endemic to Latin America, associated to significant morbimortality comprising a remarkable socioeconomic problem mainly for low-income tropical populations. The present chapter focuses translational research on Chagas disease, approaching drug combinations and repositioning, particularly exploiting the parasite oxidative stress by prospecting prooxidant compounds combined with antagonists of antioxidant systems, for developing low-cost and safe therapies for this infection. The pertinent literature on protozoal parasitic diseases is reviewed as well as on repurposing disulfiram aiming the combination with the Chagas disease drug of choice benznidazole. Both disulfiram and its first derivative sodium diethyldithiocarbamate (DETC) are able not only to inhibit p-glycoprotein, possibly reverting resistance phenotypes, but also to reduce toxicity of numerous other drugs, heavy metals, etc. Therefore, this innovation, presently in clinical research, may furnish a novel therapeutic for T. cruzi infections overcoming the adverse effects and refractory cases that impair the effectiveness of Chagas disease treatment. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Subject | Drug combination | en_US |
| Subject | Drug repositioning | en_US |
| Subject | Translational medicine | en_US |
| Subject | Chagas disease | en_US |
| Subject | Oxidative stress | en_US |
| Subject | Trypanosoma cruzi | en_US |
